Our Prices

Quantity :   1-9 Packets   10-19 Packets   20-39 Packets   40-60 Packets   Price Per Packet :     US$5.00        US$4.50        US$4.00        US$3.50

Plus $7.50 for airmail to any country. There are no additional costs.

Contact us for availability Details What is Medrol (methylprednisolone) used for? MEDROL (methylprednisolone) is indicated in the following conditions: Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Non-Endocrine Disorders: Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis post-traumatic osteoarthritis synovitis of osteoarthritis epicondylitis Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) polymyalgia rheumatica giant cell arteritis acute rheumatic carditis Dermatologic Diseases: pemphigus bullous dermatitis herpetiformis severe erythema multiforme (Stevens-Johnson syndrome) exfoliative dermatitis mycosis fungoides severe psoriasis severe seborrhoeic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis serum sickness bronchial asthma drug hypersensitivity reactions contact dermatitis atopic dermatitis Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia allergic conjunctivitis keratitis chorioretinitis optic neuritis iritis and iridocyclitis Respiratory Diseases: symptomatic sarcoidosis Loeffler's syndrome not manageable by other means berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis Haematologic Disorders: idiopathic thrombocytopenia purpura in adults secondary thrombocytopenia in adults acquired (autoimmune) haemolytic anaemia erythroblastopenia (RBC anaemia) congenital (erythroid) hypoplastic anaemia Neoplastic Diseases: For palliative management of: leukemias and lymphomas in adults acute leukaemia of childhood Edematous States:To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uraemia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: ulcerative colitis regional enteritis Nervous system: Acute exacerbations of multiple sclerosis. Management of oedema associated with brain tumour. Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. Organ Transplantations Dosage and Administration The initial dosage of MEDROL Tablets may vary from 4mg to 48mg of methylprednisolone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. Clinical situations in which high dose therapy may be indicated include multiple sclerosis (200 mg/day), cerebral oedema (200 - 1,000 mg/day), and organ transplantation (up to 7 mg/kg/day). The initial dosage should be maintained or adjusted until a satisfactory response is noted. If, after a reasonable period of time, there is a lack of satisfactory clinical response, MEDROL should be discontinued and the patient transferred to other appropriate therapy. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. Side Effects of Medrol (Methylprednisolone) The following are typical for all systemic corticosteroids. Their inclusion in this list does not necessarily indicate that the specific event has been observed with this particular medicine. Fluid and Electrolyte Disturbances: sodium retention fluid retention congestive heart failure in susceptible patients potassium loss hypokalemic alkalosis hypertension Musculoskeletal: muscle weakness steroid myopathy osteoporosis vertebral compression fractures aseptic necrosis pathologic fractures tendon rupture, particularly of the Archilles tendon Gastrointestinal: peptic ulceration with possible perforation and haemorrhage pancreatitis gastric haemorrhage perforation of the bowel oesophagitis Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT) and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversible upon discontinuation. Dermatologic: impaired wound healing thin, fragile skin petechiae and ecchymoses Neurological: increased intracranial pressure pseudotumor cerebri psychic derangements seizures Endocrine: development of Cushingoid state suppression of growth in children suppression of pituitary-adrenal axis menstrual irregularities decreased carbohydrate tolerance - manifestations of latent diabetes mellitus increased requirements for insulin or oral hypoglycemic agents in diabetics Ophthalmic: posterior subcapsular cataracts increased intraocular pressure exophthalmos Metabolic: negative nitrogen balance due to protein catabolism Immune System: masking of infections latent infections becoming active opportunistic infections hypersensitivity reactions including anaphalaxis may suppress reactions to skin tests